Fig. 6

MUC20 hinders MET activation by repressing IGF-1R lactylation in proteasome inhibitor-resistant MM cells. A Representative image of Co-IP using a MET antibody in PI-resistant KAS-6/1 and U266 cells. Rabbit IgG was used as a negative control. B MET and pMET levels in control or IGF-1R KD-transfected PI-resistant KAS-6/1 and U266 cells. C IGF-1R level in PI-sensitive, PI-resistant and MUC20 OE-transfected PI-resistant KAS-6/1 and U266 cells. D Enriched pathways in patients with MM with high and low MUC20 expression. E OCR in control or MUC20 OE-transfected PI-resistant KAS-6/1 and U266 cells. F Basal respiration and spare respiratory capacity in control or MUC20 OE-transfected PI-resistant KAS-6/1 and U266 cells. G Lactate level in control or MUC20 OE-transfected PI-resistant KAS-6/1 and U266 cells. H Representative image of Co-IP using a L-lactyl lysine antibody in control or MUC20 OE-transfected PI-resistant KAS-6/1 and U266 cells. I IGF-1R level in PI-resistant KAS-6/1 and U266 cells treated with or without exogenous lactate (lactate sodium). PR: proteasome inhibitor-resistant MM cells; OE: overexpression; OCR: oxygen consumption rate. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001